Heart, Lung and Circulation
Volume 16, Issue 1 , Pages 50-51, February 2007

Late Restenosis Following Placement of a Sirolimus Eluting Stent for In-Stent Restenosis

Department of Cardiology, Concord Repatriation General Hospital, Concord, NSW, Australia

Received 20 February 2006; accepted 3 August 2006.

Drug eluting stents (DES) are rapidly replacing intravascular brachytherapy for the treatment of bare metal in-stent restenosis (ISR). To date, there are no long-term follow up data supporting this practise. We report symptomatic repeat in-stent restenosis occurring 27 months after sirolimus eluting stent deployment for de novo in-stent restenosis. This case suggests that in a subgroup of patients with ISR, as with brachytherapy, the drug eluting stent may be simply delaying rather than inhibiting the restenotic process.

Keywords: Drug eluting stent, In-stent restenosis

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1443-9506(06)00190-9

doi:10.1016/j.hlc.2006.08.004

Heart, Lung and Circulation
Volume 16, Issue 1 , Pages 50-51, February 2007